Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)

To characterize the impact of Isturisa on clinical features and comorbidities associated with MACS. The investigators hypothesize that patients treated with Isturisa will exhibit significantly better metabolic indicators (such as fasting glucose, HbA1c, and lipid profile), blood pressure, weight, body composition and bone mineral density than at Baseline. The investigators also assess the effect of Isturisa on quality of life and psychological symptoms in patients with MACS. The investigators hypothesize that treatment with Isturisa will lead to significant improvements in quality-of-life scores and reductions in depression scores compared to Baseline.

NCT Number	NCT07247058
Lead Sponsor	Johns Hopkins University Collaborators: Recordati Rare Diseases Inc
Conditions	Mild Autonomous Cortisol Secretion (MACS)
Enrollment	10 participants
Start Date	2026-02-02
Primary Completion	2028-12 (estimated)
Study Completion	2029-03 (estimated)
Updated on ClinicalTrials.gov	2026-03-05